<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:47:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6805825" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6805825</identifier>
        <datestamp>2019-11-05</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Diabetologia</journal-id>
              <journal-id journal-id-type="iso-abbrev">Diabetologia</journal-id>
              <journal-title-group>
                <journal-title>Diabetologia</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0012-186X</issn>
              <issn pub-type="epub">1432-0428</issn>
              <publisher>
                <publisher-name>Springer Berlin Heidelberg</publisher-name>
                <publisher-loc>Berlin/Heidelberg</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6805825</article-id>
              <article-id pub-id-type="pmcid">PMC6805825</article-id>
              <article-id pub-id-type="pmc-uid">6805825</article-id>
              <article-id pub-id-type="pmid">31302707</article-id>
              <article-id pub-id-type="pmid">31302707</article-id>
              <article-id pub-id-type="publisher-id">4948</article-id>
              <article-id pub-id-type="doi">10.1007/s00125-019-4948-4</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4108-5229</contrib-id>
                  <name>
                    <surname>Oshima</surname>
                    <given-names>Megumi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jun</surname>
                    <given-names>Min</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ohkuma</surname>
                    <given-names>Toshiaki</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Toyama</surname>
                    <given-names>Tadashi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wada</surname>
                    <given-names>Takashi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cooper</surname>
                    <given-names>Mark E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hadjadj</surname>
                    <given-names>Samy</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hamet</surname>
                    <given-names>Pavel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harrap</surname>
                    <given-names>Stephen</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mancia</surname>
                    <given-names>Giuseppe</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marre</surname>
                    <given-names>Michel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williams</surname>
                    <given-names>Bryan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chalmers</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Woodward</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <address>
                    <email>mark.woodward@georgeinstitute.ox.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Perkovic</surname>
                    <given-names>Vlado</given-names>
                  </name>
                  <address>
                    <email>VPerkovic@georgeinstitute.org.au</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>on behalf of the ADVANCE Collaborative Group</collab>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.1005.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 4902 0432</institution-id><institution>The George Institute for Global Health, </institution><institution>University of New South Wales, Sydney, </institution></institution-wrap>Level 5, 1 King St, Newtown, NSW 2042 Australia </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.9707.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 3329</institution-id><institution>Department of Nephrology and Laboratory Medicine, </institution><institution>Kanazawa University, </institution></institution-wrap>Ishikawa, Japan </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.1051.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9760 5620</institution-id><institution>Diabetes Domain, </institution><institution>Baker IDI Heart and Diabetes Institute, </institution></institution-wrap>Melbourne, VIC Australia </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution>Department of Endocrinology, Institut du Thorax, </institution><institution>Inserm, CNRS, CHU Nantes, </institution></institution-wrap>Nantes, France </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.410559.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0743 2111</institution-id><institution>Centre de Recherche, </institution><institution>Centre Hospitalier de l’Université de Montréal (CRCHUM), </institution></institution-wrap>Montréal, QC Canada </aff>
                <aff id="Aff6"><label>6</label>Department of Physiology, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC Australia </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.7563.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 1754</institution-id><institution>Department of Medicine and Surgery, </institution><institution>University of Milan-Bicocca, </institution></institution-wrap>Milan, Italy </aff>
                <aff id="Aff8"><label>8</label>Department of Endocrinology, Hôpital Bichat-Claude Bernard, Université Paris, Paris, France </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>Institute of Cardiovascular Science, </institution><institution>University College London and National Institute of Health Research UCL Hospitals Biomedical Research Centre, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>The George Institute for Global Health, </institution><institution>University of Oxford, </institution></institution-wrap>1st Floor, Hayes House, 75 George Street, Oxford, OX1 2BQ UK </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution>Department of Epidemiology, </institution><institution>Johns Hopkins University, </institution></institution-wrap>Baltimore, MD USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>7</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>13</day>
                <month>7</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2019</year>
              </pub-date>
              <volume>62</volume>
              <issue>11</issue>
              <fpage>1988</fpage>
              <lpage>1997</lpage>
              <history>
                <date date-type="received">
                  <day>4</day>
                  <month>4</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>6</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2019</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Aims/hypothesis</title>
                  <p id="Par1">Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, &lt;−1.63 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> year<sup>−1</sup>) was significantly associated with the subsequent risk of the primary outcome (HR 1.30 [95% CI 1.17, 1.43]) compared with a stable change in eGFR (middle 50%, −1.63 to 0.33). An annual substantial increase in eGFR (highest 25%, &gt;0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]).</p>
                </sec>
                <sec>
                  <title>Conclusions/interpretation</title>
                  <p id="Par4">Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality.</p>
                </sec>
                <sec>
                  <title>Trial registry number</title>
                  <p id="Par5">ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (10.1007/s00125-019-4948-4) contains peer-reviewed but unedited supplementary material, which is available to authorised users.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Cardiovascular disease</kwd>
                <kwd>eGFR slope</kwd>
                <kwd>End-stage kidney disease</kwd>
                <kwd>Mortality</kwd>
                <kwd>Surrogate endpoint</kwd>
                <kwd>Type 2 diabetes</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>the John Chalmers Clinical Research Fellowship of the George Institute</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>Servier</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>the Japan Society of Women Nephrologist</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>the Scientia Fellowship from UNSW Sydney</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id>
                      <institution>Japan Society for the Promotion of Science</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer-Verlag GmbH Germany, part of Springer Nature 2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <graphic position="anchor" xlink:href="125_2019_4948_Figa_HTML" id="MO1"/>
              <p id="Par15">Diabetic kidney disease develops in approximately 40% of individuals with diabetes and can lead to poor outcomes such as end-stage kidney disease (ESKD), cardiovascular disease and premature death [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR4">4</xref>]. It is generally well known that people with diabetes have more rapid decline in kidney function compared with those without diabetes [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. Early recognition of diabetic kidney disease progression is thus critical for the prevention of such adverse long-term outcomes.</p>
              <p id="Par16">In recent years, there has been a growing interest in the assessment of the prognostic utility of short-term changes in eGFR, as well as the therapeutic utility of agents that might ameliorate these changes. Previous meta-analyses have shown significant associations among 30% and 40% decline in eGFR with subsequent risks of ESKD and mortality in individuals with and without diabetes [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. However, percentage change in eGFR in these studies was calculated using only two measurements, which largely ignores the trajectory of eGFR over time. Accordingly, recent studies have assessed eGFR slope-based approaches using multiple measurements of eGFR to determine the associations between annual change in eGFR and subsequent risk of ESKD [<xref ref-type="bibr" rid="CR10">10</xref>], cardiovascular disease [<xref ref-type="bibr" rid="CR11">11</xref>] and all-cause mortality [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. However, such studies have been limited due to the inclusion of participants with advanced chronic kidney disease (CKD) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] and relatively short periods of follow-up [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
              <p id="Par17">The objective of our study was thus to examine the prognostic value of eGFR slope in predicting clinical outcomes in individuals with type 2 diabetes, using data from the Action in Diabetes and Vascular disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, an RCT in individuals with type 2 diabetes, and its post-trial follow-up (ADVANCE Post-Trial Observational Study [ADVANCE- ON]), which has followed participants for up to 10 years post randomisation.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="FPar1">
                <title>Study design and population</title>
                <p id="Par18">Our study used data from the ADVANCE and ADVANCE-ON studies. ADVANCE (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> registration no. NCT00145925) was a 2 × 2 factorial RCT evaluating the effects of BP-lowering and intensive blood glucose-lowering treatment on vascular outcomes in individuals with type 2 diabetes. A detailed description of the design has been published previously [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. In brief, a total of 11,140 individuals with type 2 diabetes aged ≥55 years at high risk of cardiovascular events were recruited from 215 centres in 20 countries between June 2001 and March 2003. After a 6-week run-in period on open fixed low-dose perindopril-indapamide (2.0 mg/0.625 mg) and usual glucose-lowering treatment, participants were randomly assigned in a factorial design to the two treatment comparisons: a double blind comparison of the perindopril-indapamide combination (initially 2.0 mg/0.625 mg increasing to 4.0 mg/1.25 mg daily after 3 months) compared with matching placebo; and an open comparison of gliclazide-based intensive therapy (target HbA<sub>1c</sub> ≤48 mmol/mol [6.5%]) compared with standard therapy for glucose control based on routine guidelines. The median durations of follow-up for the BP- and glucose-lowering trial interventions were 4.4 and 5.0 years, respectively. The ADVANCE-ON study (ClinicalTrials.gov registration no. NCT00949286) was a post-trial follow-up study, comprising 8,494 of the 10,082 surviving participants at the end of the randomised treatment phase [<xref ref-type="bibr" rid="CR18">18</xref>]. The median total follow-up period (i.e. including both ADVANCE and ADVANCE-ON) was 9.9 years until the final visits which occurred between January 2013 and February 2014. Approvals for the original trial and the post-trial follow-up phase were obtained from the institutional review board of each centre and all participants provided written informed consent.</p>
              </sec>
              <sec id="FPar2">
                <title>Derivation of eGFR slope</title>
                <p id="Par19">The current study was restricted to those with three measurements of eGFR within a baseline period (hereinafter referred to as the eGFR slope ascertainment period) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Participants assigned to BP-lowering medication had an acute fall in eGFR during the first 4 months after randomisation compared with those assigned to placebo. An acute fall in eGFR is generally known to be induced by the initiation of BP-lowering medication that blocks the renin-angiotensin-aldosterone-system (RAAS), including ACE inhibitors (ACEis) or angiotensin-II receptor blockers (ARBs) [<xref ref-type="bibr" rid="CR19">19</xref>]. To account for this ACEi-induced fall in eGFR, in the primary analysis, the eGFR slope of each included participant was calculated based on three eGFR measurements recorded at 4, 12 and 24 months after randomisation (i.e., over a 20-month eGFR slope ascertainment period).<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design</p></caption><graphic xlink:href="125_2019_4948_Fig1_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="FPar3">
                <title>Study outcomes and follow-up</title>
                <p id="Par20">The primary outcome for this study was the composite of major renal events (defined as requirement for chronic dialysis or kidney transplantation, or death from renal disease), major macrovascular events (defined as nonfatal and fatal myocardial infarction, nonfatal and fatal stroke or other cardiovascular death) and all-cause mortality. Secondary outcomes included the individual components of the primary outcome. Participants were followed from the end of the eGFR ascertainment period until the first of the study outcomes, death or the end of follow-up (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Study outcomes recorded during the randomised treatment phase were reviewed and validated by an independent endpoint adjudication committee. Outcomes occurring during post-trial follow-up were reported by the study centres using the standardised definitions adopted during the trial, without central adjudication [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
              </sec>
              <sec id="FPar4">
                <title>Statistical methods</title>
                <p id="Par21">Continuous variables were reported as means with SDs for variables with approximately symmetrical distributions. Results for variables with skewed distributions were presented as median and interquartile range (IQR) and were transformed into natural logarithms before analysis. We summarised baseline characteristics according to quartiles of eGFR slope (&lt;−1.63 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> year<sup>−1</sup> [lowest 25%; defined as ‘substantial decrease in eGFR’], −1.63 to 0.33 [middle 50%; defined as ‘stable eGFR’] and &gt;0.33 [highest 25%; defined as ‘substantial increase in eGFR’]). Linear trends across categories of eGFR slope were tested by linear regression analysis and logistic regression analysis, as appropriate.</p>
                <p id="Par22">The eGFR slope was estimated using linear mixed models with random intercept. Cox regression models were used to estimate the adjusted HRs and their corresponding 95% CIs for categories of eGFR slope and to compare a substantial decrease in eGFR with stable eGFR and a substantial increase in eGFR with stable eGFR. Cox models were adjusted for covariates including registration values of age, sex, region of residence (Asia or non-Asia), duration of diabetes, log-transformed urine albumin/creatinine ratio (UACR), systolic BP and diastolic BP, a history of macrovascular disease, smoking habits, drinking habits, treated hypertension, HbA<sub>1c</sub>, HDL-cholesterol, LDL-cholesterol, log-transformed triacylglycerol and BMI, 4-month eGFR (at the beginning of the eGFR slope ascertainment period, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation [<xref ref-type="bibr" rid="CR20">20</xref>]), and ADVANCE randomised treatment allocation (BP and glucose treatment). A test for linear trend was performed using the category of eGFR slope as a continuous variable in Cox models. An additional quadratic term for eGFR slope was also fitted in Cox models to test for a residual quadratic effect. In addition, restricted cubic splines for eGFR slopes were fitted using no change in eGFR (0 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> year<sup>−1</sup>) as the reference point (knots were placed at −5, −3, −1, 1 and 3 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> year<sup>−1</sup>, as used in previous studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]).</p>
                <p id="Par23">We performed the subgroup analyses according to covariates including sex, region of residence, eGFR (&lt;60, 60–89 or ≥90 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup>) and UACR (&lt;30, 30–300 or &gt;300 μg/mg) at registration and ADVANCE randomised treatment allocation (BP- and glucose-lowering treatment). For sensitivity analyses, we repeated the analysis by using eGFR measurements at the following study points (Fig. <xref rid="Fig1" ref-type="fig">1</xref>): (1) 4 and 12 months after randomisation (i.e., over an 8-month eGFR slope ascertainment period); and (2) 4, 12, 24 and 36 months after randomisation (i.e., over a 32-month eGFR slope ascertainment period).</p>
                <p id="Par24">Considering that both 30% and 40% declines in eGFR are sometimes used as surrogate endpoints for CKD progression, sensitivity analyses used percentage change in eGFR (calculated based on two eGFR measurements recorded at 4 and 24 months after randomisation) instead of eGFR slope. We used the Akaike information criterion, the Schwarz’s Bayesian information criterion and c-statistics to assess the discrimination of the Cox models for predicting study outcomes by including eGFR slope or percentage change in eGFR in addition to covariates.</p>
                <p id="Par25">All analyses were conducted using Stata/MP, version 15 (Stata Corporation, College Station, TX, USA). A two-sided <italic>p</italic> value &lt;0.05 was considered statistically significant.</p>
              </sec>
            </sec>
            <sec id="Sec3">
              <title>Results</title>
              <sec id="FPar5">
                <title>Patient characteristics</title>
                <p id="Par26">Of the 11,140 participants in the ADVANCE trial, 8,879 individuals (80%) were included in our final cohort (electronic supplementary material [ESM] Fig. <xref rid="MOESM1" ref-type="media">1</xref>). The mean age of the cohort was 65.6 years (SD 6.3), 58% were men, the mean duration of diabetes was 7.8 years at registration (SD 6.3), the mean eGFR was 75 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> (SD 17) and the median UACR was 14 μg/mg (IQR 7–38) (Table <xref rid="Tab1" ref-type="table">1</xref>). Registration characteristics of participants in this cohort were approximately similar to those of the entire trial population (ESM Table <xref rid="MOESM1" ref-type="media">1</xref>) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The mean annual change in eGFR was −0.63 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> (SD 1.75) (ESM Fig. <xref rid="MOESM1" ref-type="media">2</xref>). Compared with participants with stable eGFR (middle 50%, −1.63 to 0.33 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> year<sup>−1</sup>), those with a substantial decrease in eGFR (lowest 25%, &lt;−1.63) were more likely to be older, a non-smoker, to have a history of macrovascular disease and to have higher levels of albuminuria and lower levels of eGFR. In the multivariable analysis for risk factors associated with eGFR slopes (ESM Table <xref rid="MOESM1" ref-type="media">2</xref>), the mean eGFR slope of decline was steeper in individuals with older age, higher levels of UACR and HbA<sub>1c</sub>, and lower level of HDL-cholesterol, while the mean eGFR slope was flatter in individuals with lower eGFR.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Registration characteristics according to categories of eGFR slopes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristic</th><th rowspan="2">Total</th><th colspan="4">eGFR slopes (ml min<sup>-1</sup> [1.73 m]<sup>-2</sup> year<sup>-1</sup>)</th></tr><tr><th>Substantial decrease in eGFR Lowest 25% (&lt;-1.63)</th><th>Stable eGFR Middle 50% (-1.63 to 0.33)</th><th>Substantial increase in eGFR Highest 25% (&gt;0.33)</th><th>p for trend</th></tr></thead><tbody><tr><td><italic>N</italic></td><td>8879</td><td>2220</td><td>4440</td><td>2219</td><td/></tr><tr><td>Age (years; mean [SD])</td><td>65.6 (6.3)</td><td>66.0 (6.4)</td><td>65.8 (6.3)</td><td>64.6 (6.1)</td><td>&lt;0.001</td></tr><tr><td>Men (<italic>n</italic> [%])</td><td>5108 (58)</td><td>1160 (52)</td><td>2730 (61)</td><td>1218 (55)</td><td>0.08</td></tr><tr><td>Residence in Asia (<italic>n</italic> [%])</td><td>3523 (40)</td><td>915 (41)</td><td>1590 (36)</td><td>1018 (46)</td><td>0.002</td></tr><tr><td>Duration of diabetes (years; mean [SD])</td><td>7.8 (6.3)</td><td>8.1 (6.2)</td><td>7.6 (6.2)</td><td>8.0 (6.5)</td><td>0.86</td></tr><tr><td>History of macrovascular disease (<italic>n</italic> [%])</td><td>2742 (31)</td><td>741 (33)</td><td>1349 (30)</td><td>652 (29)</td><td>0.004</td></tr><tr><td>Current treated hypertension (<italic>n</italic> [%])</td><td>6050 (68)</td><td>1580 (72)</td><td>2988 (67)</td><td>1482 (67)</td><td>0.002</td></tr><tr><td>Current smoking (<italic>n</italic> [%])</td><td>1224 (14)</td><td>255 (11)</td><td>617 (14)</td><td>352 (16)</td><td>&lt;0.001</td></tr><tr><td>Current alcohol drinking (<italic>n</italic> [%])</td><td>2638 (30)</td><td>561 (25)</td><td>1466 (33)</td><td>611 (28)</td><td>0.10</td></tr><tr><td>UACR (μg/mg; median [IQR])</td><td>14 (7–38)</td><td>17 (8–48)</td><td>14 (7–35)</td><td>13 (7–33)</td><td>&lt;0.001</td></tr><tr><td>eGFR (ml min<sup>−1</sup> [1.73 m]<sup>−2</sup>; mean [SD])</td><td>75 (17)</td><td>74 (18)</td><td>75 (18)</td><td>77 (16)</td><td>&lt;0.001</td></tr><tr><td>Systolic BP (mmHg; mean [SD])</td><td>145 (21)</td><td>145 (22)</td><td>144 (21)</td><td>144 (21)</td><td>0.04</td></tr><tr><td>Diastolic BP (mmHg; mean [SD])</td><td>81 (11)</td><td>80 (11)</td><td>81 (11)</td><td>81 (11)</td><td>0.35</td></tr><tr><td>HbA<sub>1c</sub> (mmol/mol; mean [SD])</td><td>58 (16)</td><td>60 (17)</td><td>58 (16)</td><td>57 (16)</td><td>&lt;0.001</td></tr><tr><td>HbA<sub>1c</sub> (%; mean [SD])</td><td>7.5 (1.5)</td><td>7.6 (1.6)</td><td>7.5 (1.5)</td><td>7.4 (1.5)</td><td>&lt;0.001</td></tr><tr><td>HDL-cholesterol (mmol/l; mean [SD])</td><td>1.3 (0.3)</td><td>1.2 (0.3)</td><td>1.3 (0.3)</td><td>1.3 (0.4)</td><td>0.002</td></tr><tr><td>LDL-cholesterol (mmol/l; mean [SD])</td><td>3.1 (1.0)</td><td>3.1 (1.0)</td><td>3.1 (1.0)</td><td>3.2 (1.1)</td><td>0.006</td></tr><tr><td>Triacylglycerol (mmol/l; median [IQR])</td><td>2.0 (1.2–2.3)</td><td>1.7 (1.2–2.4)</td><td>1.6 (1.2–2.3)</td><td>1.6 (1.1–2.3)</td><td>0.21</td></tr><tr><td>BMI (kg/m<sup>2</sup>; mean [SD])</td><td>28.2 (5.2)</td><td>28.3 (5.5)</td><td>28.3 (5.1)</td><td>27.9 (4.9)</td><td>0.01</td></tr><tr><td>Randomised BP-lowering treatment (<italic>n</italic> [%])</td><td>4438 (50)</td><td>1180 (53)</td><td>2199 (50)</td><td>1059 (48)</td><td>&lt;0.001</td></tr><tr><td><p>Randomised intensive blood glucose control</p><p>(<italic>n</italic> [%])</p></td><td>4486 (51)</td><td>1151 (52)</td><td>2249 (51)</td><td>1086 (49)</td><td>0.05</td></tr></tbody></table><table-wrap-foot><p>Asia includes China, India, Malaysia and the Philippines</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="FPar6">
                <title>Clinical outcomes during follow-up</title>
                <p id="Par27">Over a median follow-up period of 7.6 years (IQR 3.8–8.7) following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary composite outcome (117 major renal events [1.3%], 1,395 major macrovascular events [16%] and 1,450 deaths [16%]). Overall, we observed a strong negative linear association between the category of eGFR slope and subsequent risk of the primary composite outcome (<italic>p</italic> for linear trend &lt;0.001; <italic>p</italic> for quadratic effect 0.01; Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Compared with stable eGFR, a substantial decrease in eGFR was significantly associated with an increased risk of the primary study outcome (HR 1.30 [95% CI 1.17, 1.43]; <italic>p</italic> &lt; 0.001), whereas a substantial increase in eGFR had no effect (HR 0.96 [95% CI 0.86, 1.07]; <italic>p</italic> &lt; 0.42). We observed similar associations between categories of eGFR slope and the risk of the individual components of the primary composite outcome: increased risk for a substantial decrease in eGFR, but no evidence of a difference in risk for a substantial increase in eGFR, compared with stable eGFR. As shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>, greater annual declines in eGFR were associated with higher risks of study outcomes compared with no change in eGFR (0 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> year<sup>−1</sup>). Among participants with eGFR slopes of −3 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup>, adjusted HRs were 1.37 (95% CI 1.20, 1.56) for the primary outcome, 6.14 (3.60, 10.49) for major renal events, 1.25 (1.06, 1.48) for major macrovascular events and 1.54 (1.31, 1.81) for all-cause mortality (ESM Table <xref rid="MOESM1" ref-type="media">3</xref>). There was also a significant linear association between estimated eGFR slope and the risk of the primary outcome (<italic>p</italic> for linear trend &lt;0.001; <italic>p</italic> for quadratic effect 0.18) (ESM Table <xref rid="MOESM1" ref-type="media">3</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Adjusted HRs for study outcomes according to categories of eGFR slope over the 20-month eGFR slope ascertainment period. Covariates: registration values of age, sex, region of residence, duration of diabetes, log-transformed UACR, systolic BP, diastolic BP, a history of macrovascular disease, smoking, drinking, treated hypertension, HbA<sub>1c</sub>, HDL-cholesterol, LDL-cholesterol, log-transformed triacylglycerol and BMI, 4-month eGFR and randomised treatment allocation (BP and glucose treatment)</p></caption><graphic xlink:href="125_2019_4948_Fig2_HTML" id="MO3"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Spline curves showing adjusted HRs and 95% CIs (shaded) for (<bold>a</bold>) combined major renal events, macrovascular events and all-cause mortality (primary outcome), (<bold>b</bold>) major renal events, (<bold>c</bold>) major macrovascular events and (<bold>d</bold>) all-cause mortality, associated with eGFR slopes over the 20-month eGFR slope ascertainment period. Values were trimmed at a slope of &lt;−5.4 and &gt;3.8 ml min<sup>-1</sup> (1.73 m)<sup>-2</sup> year<sup>-1</sup> (each included 1.0% of participants). Knots were placed at -5, -3, -1, 1 and 3 ml min<sup>-1</sup> (1.73 m)<sup>-2</sup> year<sup>-1</sup>, using 0 ml min<sup>-1</sup> (1.73 m)<sup>-2</sup> year<sup>-1</sup> as the reference point. Covariates: registration values of age, sex, region of residence, duration of diabetes, log-transformed UACR, systolic BP, diastolic BP, a history of macrovascular disease, smoking, drinking, treated hypertension, HbA<sub>1c</sub>, HDL-cholesterol, LDL-cholesterol, log-transformed triacylglycerol and BMI, 4-month eGFR and randomised treatment allocation (BP and glucose treatment)</p></caption><graphic xlink:href="125_2019_4948_Fig3_HTML" id="MO4"/></fig></p>
              </sec>
              <sec id="FPar7">
                <title>Subgroup and sensitivity analysis</title>
                <p id="Par28">Overall trends remained unchanged across participant groups defined by sex, region of residence, eGFR and UACR at registration and randomised treatment allocation (BP- and glucose-lowering treatment) (ESM Fig. <xref rid="MOESM1" ref-type="media">3</xref>). In sensitivity analyses, the associations were similar when using four measurements of eGFR over the 32-month eGFR slope ascertainment period, but flatter when using two measurements of eGFR over the 8-month eGFR slope ascertainment period, compared with the primary analysis using three measurements over the 20-month eGFR slope ascertainment period (ESM Fig. <xref rid="MOESM1" ref-type="media">4</xref>).</p>
                <p id="Par29">Similar associations were observed when assessing percentage change in eGFR (ESM Fig. <xref rid="MOESM1" ref-type="media">5</xref>). Compared with the model including percentage change in eGFR in addition to covariates, replacing percentage change in eGFR with eGFR slope did not significantly change the discrimination for predicting clinical outcomes (ESM Table <xref rid="MOESM1" ref-type="media">4</xref>).</p>
              </sec>
            </sec>
            <sec id="Sec4">
              <title>Discussion</title>
              <p id="Par30">In a post hoc analysis of 8,879 participants from a large RCT, we observed a strong association between annual change in kidney function and the future risk of major clinical outcomes in type 2 diabetes. We found that an annual substantial decrease in eGFR over 20 months exhibited a statistically significant association with increased risks of major renal events, major macrovascular events and all-cause mortality, independent of baseline kidney function, albuminuria and other covariates, consistently observed across various patient subgroups of covariates. Although an annual substantial increase in eGFR did not significantly predict the risk of these outcomes, our results from multiple analyses supported the utility of eGFR slopes for predicting the subsequent vascular outcomes and all-cause death in type 2 diabetes.</p>
              <p id="Par31">A limited number of studies have shown the relationship between eGFR slopes and the subsequent risk of ESKD [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], cardiovascular disease [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] and all-cause mortality [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. Results from a meta-analysis of 13 CKD cohorts showed that an eGFR slope of −3 vs 0 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> over 3 years was associated with the risk of ESKD (HR 1.73 [95% CI 1.50, 2.00]) after adjusting for last measurement of eGFR [<xref ref-type="bibr" rid="CR10">10</xref>]. In a cohort of 529,312 adults in the Alberta Kidney Disease Network, an eGFR slope of −4 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> was associated with 74%, 16% and 21% higher risks of congestive heart failure, acute myocardial infarction and stroke, respectively, compared with no change in eGFR [<xref ref-type="bibr" rid="CR11">11</xref>]. In a cohort of French individuals with type 2 diabetes, annual eGFR decline over 6.3 years of follow-up was greater in individuals with major cardiovascular events compared with those without (−3.0 vs −1.7 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> year<sup>−1</sup>) [<xref ref-type="bibr" rid="CR22">22</xref>]. Furthermore, a meta-analysis of 12 CKD cohorts within the CKD Prognosis Consortium showed that an eGFR slope of −6 vs 0 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> over 3 years was associated with an adjusted HR for all-cause mortality of 1.25 (95% CI 1.09, 1.44) after adjusting for last measurement of eGFR [<xref ref-type="bibr" rid="CR14">14</xref>]. However, these results were mostly based on general or CKD populations. Therefore, the current study was notable for evaluating the composite outcome of major renal and macrovascular events and all-cause mortality in a large population with type 2 diabetes after adjusting for important risk factors of kidney disease progression.</p>
              <p id="Par32">Various mechanisms have been suggested to explain why declining kidney function is associated with increased risk of cardiovascular disease and all-cause mortality as well as renal outcome. Decrease in eGFR may exacerbate cardiovascular risk factors such as BP and lipids [<xref ref-type="bibr" rid="CR23">23</xref>]. Other possible factors which were not measured in our cohort include activation of the RAAS, endothelial dysfunction, inflammation and oxidative stress [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. On the other hand, these risk factors and progression of cardiovascular disease certainly accelerate the progression of CKD [<xref ref-type="bibr" rid="CR26">26</xref>]. In addition, worsening kidney function may cause decreased appetite, decreased physical function and overall frailty, and indirectly result in higher mortality risk [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
              <p id="Par33">There has been increasing interest in the utility of eGFR slope as a surrogate endpoint for predicting subsequent ESKD in clinical trials, but a clear definition of the magnitude of eGFR slope as a surrogate endpoint has not been established. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guideline defined rapid eGFR decline as a sustained decline in eGFR of greater than −5 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> [<xref ref-type="bibr" rid="CR27">27</xref>], which was supported by other studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. A number of studies already used eGFR slope greater than −5 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> as a substitute for kidney outcome, which suggested the potential of eGFR slope of −5 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> as a surrogate endpoint. However, in the present study (approximately 80% had early-stage diabetic kidney disease at baseline with eGFR ≥60 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> and UACR &lt;300 μg/mg), only 1.4% of participants developed eGFR decline greater than −5 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup>. Instead, more than fivefold participants developed eGFR slopes of −3 vs −5 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> and their risks of major renal events were weaker but still robustly increased. Therefore, the potential of using eGFR slopes less than −5 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> may be a future subject to be assessed for seeking more practical surrogate endpoints in people with type 2 diabetes.</p>
              <p id="Par34">The standard duration for estimating eGFR slopes is also unknown. We excluded the first 4 months after randomisation from the eGFR slope ascertainment period, in order to remove an acute pharmacological effect of ACEi on eGFR. RAAS blockers, including ACEis and ARBs, are largely known to prevent the onset and progression of diabetic kidney disease and improve survival rate in people with diabetes [<xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. During the initiation of RAAS blockers, there may be an acute fall in eGFR [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], because RAAS blockers inhibit angiotensin 2-mediated renal vasoconstriction which in turn causes a reduction in intraglomerular pressure and filtration fraction. Thus, in people starting RAAS blockers, changes in eGFR over time should be evaluated separately during the initial months when an acute fall in eGFR is observed, and during subsequent periods until the end of follow-up.</p>
              <p id="Par35">Currently, both 30% and 40% declines in eGFR are widely accepted as surrogate endpoints for CKD progression, based on a series of meta-analyses and simulations [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In this study, similar associations were observed when using percentage change in eGFR and eGFR slope, and the discrimination statistics in the model including eGFR slope were similar to those using percentage change in eGFR for predicting major clinical outcomes. This may be consistent with a previous report [<xref ref-type="bibr" rid="CR32">32</xref>]. The eGFR slope can potentially reflect the course of changes in kidney function more accurately than percentage change in eGFR, because the slope takes into account all of the available eGFR measurements of an individual over time. Our study indicated that evaluating eGFR slope in an individual might be a promising alternative to percentage change in eGFR for predicting the progression of diabetic kidney disease.</p>
              <p id="Par36">Recently, a number of clinical trials have assessed the effects of sodium glucose cotransporter 2 inhibitors in people with type 2 diabetes. Among the trials with similar baseline renal characteristics to our cohort, the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program (mean eGFR 77 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> [SD 21]) reported that participants allocated to the placebo group had a mean annual long-term decline in eGFR of −0.9 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> [<xref ref-type="bibr" rid="CR33">33</xref>]. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial (mean eGFR 74 ml min<sup>−1</sup> [1.73 m]<sup>−2</sup> [<xref ref-type="bibr" rid="CR22">22</xref>]) observed a mean annual change in eGFR of −1.46 ml min<sup>−1</sup> (1.73 m)<sup>−2</sup> year<sup>−1</sup> in the placebo group [<xref ref-type="bibr" rid="CR34">34</xref>]. Our cohort included a lower-risk population showing slower decline in eGFR compared with these trials.</p>
              <p id="Par37">The strengths of our study include the large number and diverse groups of participants, the long duration of follow-up, the sequential measurements of eGFR during the ADVANCE trial and the ability to adjust for multiple important risk factors. Also, we used linear mixed models, which are more robust than ordinary linear regression models, to estimate eGFR slopes and assess changes over time in participants with varying intervals between measurements [<xref ref-type="bibr" rid="CR35">35</xref>]. However, our study has several limitations. First, as our study cohort was derived from a randomised trial, the results may limit generalisability to broader populations. Second, only 84% of the participants alive at the end of the ADVANCE trial were enrolled in the post-trial follow-up (ADVANCE-ON trial). However, baseline characteristics of those included in the ADVANCE-ON trial were similar to those of the entire trial population [<xref ref-type="bibr" rid="CR18">18</xref>]. Third, we used eGFR instead of a directly measured GFR to calculate GFR slopes, which may lead to some misclassification of true course of change in kidney function [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Finally, our models to estimate eGFR slopes did not consider non-linear and time-varying patterns of eGFR decline. However, a previous study showed that slopes were linear for 83% of individuals with diabetes and normal kidney function [<xref ref-type="bibr" rid="CR38">38</xref>]. Also, estimating eGFR slope may be subject to measurement error including regression to the mean [<xref ref-type="bibr" rid="CR39">39</xref>].</p>
              <p id="Par38">In conclusion, an annual substantial decrease in eGFR over 20 months was strongly associated with the future risk of renal and cardiovascular events and all-cause mortality in type 2 diabetes, supporting the potential for using eGFR slope as a predictor for major clinical outcomes. The present analysis suggests that monitoring eGFR over time is beneficial to identifying individuals with diabetes at high risk of vascular outcomes and all-cause death, requiring close monitoring for early initiation of appropriate preventive and therapeutic strategies.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Electronic supplementary material</title>
              <sec id="Sec5">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="125_2019_4948_MOESM1_ESM.pdf">
                      <label>ESM 1</label>
                      <caption>
                        <p>(PDF 1149 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>ACEi</term>
                  <def>
                    <p id="Par6">ACE inhibitor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ADVANCE</term>
                  <def>
                    <p id="Par7">The Action in Diabetes and Vascular disease: Preterax and Diamicron MR Controlled Evaluation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ADVANCE-ON</term>
                  <def>
                    <p id="Par8">ADVANCE Post-Trial Observational Study</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ARB</term>
                  <def>
                    <p id="Par9">Angiotensin-II receptor blocker</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CKD</term>
                  <def>
                    <p id="Par10">Chronic kidney disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ESKD</term>
                  <def>
                    <p id="Par11">End-stage kidney disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IQR</term>
                  <def>
                    <p id="Par12">Interquartile range</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RAAS</term>
                  <def>
                    <p id="Par13">Renin-angiotensin-aldosterone-system</p>
                  </def>
                </def-item>
                <def-item>
                  <term>UACR</term>
                  <def>
                    <p id="Par14">Urine albumin/creatinine ratio</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher’s note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <notes notes-type="author-contribution">
              <title>Contribution statement</title>
              <p>MO, MJ, TO, TT, JC, MW and VP contributed to the concept and rationale for this study. MO conducted statistical analysis with advice from MJ, TO, TT, VP, JC and MW. All authors were involved in data interpretation. MO, MJ, TO, TT, JC, MW and VP contributed to discussion. MO and MJ drafted the manuscript. All authors reviewed and edited the manuscript and approved the final submitted version. JC, MW and VP are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>The ADVANCE trial was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia and Servier. MO, TT and TW are supported by the Japan Society for the Promotion of Science Program for Fostering Globally Talented Researchers. MO is supported by the Japanese Society of Women Nephrologists. TO is supported by the John Chalmers Clinical Research Fellowship of the George Institute. MJ is supported by a Scientia Fellowship from University of New South Wales, Sydney. JC received research grants from the NHMRC of Australia for the ADVANCE trial and ADVANCE-ON post-trial follow-up. MW is an NHMRC of Australia Principal Research Fellow (1080206).</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.</p>
            </notes>
            <notes>
              <title>Duality of interest</title>
              <notes notes-type="COI-statement">
                <p>MO, TO, TT and TW report no conflicts of interest. MJ reports receiving grant support from the NHMRC of Australia (Project Grant: 1148060) and unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. MEC received consulting fees from Merck, GlaxoSmithKline, Amgen and AstraZeneca, and lecture fees from Servier. SaH reports personal fees and non-financial support from AstraZeneca, Bristol-Myers Squibb, Janssen, MSD and Sanofi, and personal fees from Abbott, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Novo Nordisk, Servier and Takeda. PH received consulting fees from Servier. StH reports lecture fees from Servier, Takeda and Novartis. GM reports personal fees from Servier, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Novartis, Menarini Group, Recordati and Takeda Pharmaceutical Company. MM received personal fees from Novo Nordisk, Sanofi, Eli Lilly and Company, Merck Sharp &amp; Dohme, Abbott, Novartis, Servier and AstraZeneca, and grant support from Novo Nordisk, Sanofi, Eli Lilly and Company, Merck Sharp &amp; Dohme and Novartis. BW received lecture fees from Servier, Novartis, Daiichi Sankyo, Pfizer and Boehringer Ingelheim, and serves on trial steering committees for Novartis, Relypsa and Vascular Dynamics. JC received research grants from the NHMRC of Australia and from Servier for the ADVANCE trial and ADVANCE-ON post-trial follow-up, and honoraria for speaking about these studies at scientific meetings. MW reports consultancy fees from Amgen and Kirin and grant support from the NHMRC. VP reports honoraria for scientific lectures from Boehringer Ingelheim, Merck, AbbVie, Roche, AstraZeneca and Servier, and serves on steering committees and advisory boards supported by AbbVie, Astellas, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen and Pfizer.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <mixed-citation publication-type="other">Australian Institute of Health and Welfare (2018) Deaths from diabetes. Available from <ext-link ext-link-type="uri" xlink:href="https://www.aihw.gov.au/reports/diabetes/diabetes-snapshot/contents/deaths-from-diabetes">https://www.aihw.gov.au/reports/diabetes/diabetes-snapshot/contents/deaths-from-diabetes</ext-link>. Accessed 15 Oct 2018</mixed-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tuttle</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Bakris</surname>
                      <given-names>GL</given-names>
                    </name>
                    <name>
                      <surname>Bilous</surname>
                      <given-names>RW</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Diabetic kidney disease: a report from an ADA Consensus Conference</article-title>
                  <source>Diabetes Care</source>
                  <year>2014</year>
                  <volume>37</volume>
                  <issue>10</issue>
                  <fpage>2864</fpage>
                  <lpage>2883</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc14-1296</pub-id>
                  <?supplied-pmid 4170131?>
                  <pub-id pub-id-type="pmid">25249672</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>The United States Renal Data System</collab>
                  </person-group>
                  <source>2017 USRDS annual data report: Epidemiology of kidney disease in the United States</source>
                  <year>2017</year>
                  <publisher-loc>Bethesda, MD</publisher-loc>
                  <publisher-name>National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ninomiya</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Perkovic</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>de Galan</surname>
                      <given-names>BE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2009</year>
                  <volume>20</volume>
                  <issue>8</issue>
                  <fpage>1813</fpage>
                  <lpage>1821</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2008121270</pub-id>
                  <?supplied-pmid 19443635?>
                  <pub-id pub-id-type="pmid">19443635</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hobeika</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Hunt</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Neely</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Arthur</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of the rate of renal function decline in nonproteinuric patients with and without diabetes</article-title>
                  <source>Am J Med Sci</source>
                  <year>2015</year>
                  <volume>350</volume>
                  <issue>6</issue>
                  <fpage>447</fpage>
                  <lpage>452</lpage>
                  <pub-id pub-id-type="doi">10.1097/MAJ.0000000000000583</pub-id>
                  <?supplied-pmid 26624901?>
                  <pub-id pub-id-type="pmid">26624901</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zoppini</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Targher</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Chonchol</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function</article-title>
                  <source>Clin J Am Soc Nephrol</source>
                  <year>2012</year>
                  <volume>7</volume>
                  <issue>3</issue>
                  <fpage>401</fpage>
                  <lpage>408</lpage>
                  <pub-id pub-id-type="doi">10.2215/CJN.07650711</pub-id>
                  <?supplied-pmid 22282481?>
                  <pub-id pub-id-type="pmid">22282481</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Warren</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Rebholz</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Sang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Diabetes and trajectories of estimated glomerular filtration rate: a prospective cohort analysis of the Atherosclerosis Risk in Communities study</article-title>
                  <source>Diabetes Care</source>
                  <year>2018</year>
                  <volume>41</volume>
                  <issue>8</issue>
                  <fpage>1646</fpage>
                  <lpage>1653</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc18-0277</pub-id>
                  <?supplied-pmid 29858211?>
                  <pub-id pub-id-type="pmid">29858211</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coresh</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Turin</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Matsushita</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality</article-title>
                  <source>JAMA</source>
                  <year>2014</year>
                  <volume>311</volume>
                  <issue>24</issue>
                  <fpage>2518</fpage>
                  <lpage>2531</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2014.6634</pub-id>
                  <?supplied-pmid 24892770?>
                  <pub-id pub-id-type="pmid">24892770</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lambers Heerspink</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Tighiouart</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Sang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials</article-title>
                  <source>Am J Kidney Dis</source>
                  <year>2014</year>
                  <volume>64</volume>
                  <issue>6</issue>
                  <fpage>860</fpage>
                  <lpage>866</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.ajkd.2014.08.018</pub-id>
                  <?supplied-pmid 25441439?>
                  <pub-id pub-id-type="pmid">25441439</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kovesdy</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Coresh</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ballew</surname>
                      <given-names>SH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Past decline versus current eGFR and subsequent ESRD risk</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2016</year>
                  <volume>27</volume>
                  <issue>8</issue>
                  <fpage>2447</fpage>
                  <lpage>2455</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2015060687</pub-id>
                  <?supplied-pmid 26657867?>
                  <pub-id pub-id-type="pmid">26657867</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Turin</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Jun</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>James</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Magnitude of rate of change in kidney function and future risk of cardiovascular events</article-title>
                  <source>Int J Cardiol</source>
                  <year>2016</year>
                  <volume>202</volume>
                  <fpage>657</fpage>
                  <lpage>665</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijcard.2015.09.090</pub-id>
                  <?supplied-pmid 26453813?>
                  <pub-id pub-id-type="pmid">26453813</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Turin</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Coresh</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tonelli</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Change in the estimated glomerular filtration rate over time and risk of all-cause mortality</article-title>
                  <source>Kidney Int</source>
                  <year>2013</year>
                  <volume>83</volume>
                  <issue>4</issue>
                  <fpage>684</fpage>
                  <lpage>691</lpage>
                  <pub-id pub-id-type="doi">10.1038/ki.2012.443</pub-id>
                  <?supplied-pmid 23344477?>
                  <pub-id pub-id-type="pmid">23344477</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Al-Aly</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Zeringue</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fu</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Rate of kidney function decline associates with mortality</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2010</year>
                  <volume>21</volume>
                  <issue>11</issue>
                  <fpage>1961</fpage>
                  <lpage>1969</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2009121210</pub-id>
                  <?supplied-pmid 20947634?>
                  <pub-id pub-id-type="pmid">20947634</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Naimark</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Grams</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Matsushita</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Past decline versus current eGFR and subsequent mortality risk</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2016</year>
                  <volume>27</volume>
                  <issue>8</issue>
                  <fpage>2456</fpage>
                  <lpage>2466</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2015060688</pub-id>
                  <?supplied-pmid 26657865?>
                  <pub-id pub-id-type="pmid">26657865</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>ADVANCE Management Committee</collab>
                  </person-group>
                  <article-title>Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease – Preterax and Diamicron MR Controlled Evaluation</article-title>
                  <source>Diabetologia</source>
                  <year>2001</year>
                  <volume>44</volume>
                  <fpage>1118</fpage>
                  <lpage>1120</lpage>
                  <pub-id pub-id-type="doi">10.1007/s001250100612</pub-id>
                  <pub-id pub-id-type="pmid">11596665</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patel</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>MacMahon</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chalmers</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <year>2007</year>
                  <volume>370</volume>
                  <issue>9590</issue>
                  <fpage>829</fpage>
                  <lpage>840</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61303-8</pub-id>
                  <?supplied-pmid 17765963?>
                  <pub-id pub-id-type="pmid">17765963</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patel</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>MacMahon</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chalmers</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title>
                  <source>N Engl J Med</source>
                  <year>2008</year>
                  <volume>358</volume>
                  <fpage>2560</fpage>
                  <lpage>2572</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMicm066227</pub-id>
                  <pub-id pub-id-type="pmid">18539916</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zoungas</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chalmers</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Neal</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Follow-up of blood-pressure lowering and glucose control in type 2 diabetes</article-title>
                  <source>N Engl J Med</source>
                  <year>2014</year>
                  <volume>371</volume>
                  <issue>15</issue>
                  <fpage>1392</fpage>
                  <lpage>1406</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1407963</pub-id>
                  <?supplied-pmid 25234206?>
                  <pub-id pub-id-type="pmid">25234206</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Holtkamp</surname>
                      <given-names>FA</given-names>
                    </name>
                    <name>
                      <surname>de Zeeuw</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>MC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function</article-title>
                  <source>Kidney Int</source>
                  <year>2011</year>
                  <volume>80</volume>
                  <issue>3</issue>
                  <fpage>282</fpage>
                  <lpage>287</lpage>
                  <pub-id pub-id-type="doi">10.1038/ki.2011.79</pub-id>
                  <?supplied-pmid 21451458?>
                  <pub-id pub-id-type="pmid">21451458</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Levey</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Stevens</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Schmid</surname>
                      <given-names>CH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A new equation to estimate glomerular filtration rate</article-title>
                  <source>Ann Intern Med</source>
                  <year>2009</year>
                  <volume>150</volume>
                  <issue>9</issue>
                  <fpage>604</fpage>
                  <lpage>612</lpage>
                  <pub-id pub-id-type="doi">10.7326/0003-4819-150-9-200905050-00006</pub-id>
                  <?supplied-pmid 19414839?>
                  <pub-id pub-id-type="pmid">19414839</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>KDIGO CKD Work Group</collab>
                  </person-group>
                  <article-title>KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease</article-title>
                  <source>Kidney Int Suppl</source>
                  <year>2013</year>
                  <volume>3</volume>
                  <fpage>1</fpage>
                  <lpage>150</lpage>
                  <pub-id pub-id-type="doi">10.1038/kisup.2012.73</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ragot</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Saulnier</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Velho</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dynamic changes in renal function are associated with major cardiovascular events in patients with type 2 diabetes</article-title>
                  <source>Diabetes Care</source>
                  <year>2016</year>
                  <volume>39</volume>
                  <issue>7</issue>
                  <fpage>1259</fpage>
                  <lpage>1266</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc15-2607</pub-id>
                  <?supplied-pmid 27222502?>
                  <pub-id pub-id-type="pmid">27222502</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Matsushita</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Selvin</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bash</surname>
                      <given-names>LD</given-names>
                    </name>
                    <name>
                      <surname>Franceschini</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Astor</surname>
                      <given-names>BC</given-names>
                    </name>
                    <name>
                      <surname>Coresh</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Change in estimated GFR associates with coronary heart disease and mortality</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2009</year>
                  <volume>20</volume>
                  <issue>12</issue>
                  <fpage>2617</fpage>
                  <lpage>2624</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2009010025</pub-id>
                  <?supplied-pmid 19892932?>
                  <pub-id pub-id-type="pmid">19892932</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schiffrin</surname>
                      <given-names>EL</given-names>
                    </name>
                    <name>
                      <surname>Lipman</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>JF</given-names>
                    </name>
                  </person-group>
                  <article-title>Chronic kidney disease: effects on the cardiovascular system</article-title>
                  <source>Circulation</source>
                  <year>2007</year>
                  <volume>116</volume>
                  <issue>1</issue>
                  <fpage>85</fpage>
                  <lpage>97</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.678342</pub-id>
                  <?supplied-pmid 17606856?>
                  <pub-id pub-id-type="pmid">17606856</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Navarro-Gonzalez</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Mora-Fernandez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Muros de Fuentes</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Garcia-Perez</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy</article-title>
                  <source>Nat Rev Nephrol</source>
                  <year>2011</year>
                  <volume>7</volume>
                  <issue>6</issue>
                  <fpage>327</fpage>
                  <lpage>340</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrneph.2011.51</pub-id>
                  <?supplied-pmid 21537349?>
                  <pub-id pub-id-type="pmid">21537349</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Whelton</surname>
                      <given-names>PK</given-names>
                    </name>
                    <name>
                      <surname>Carey</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Aronow</surname>
                      <given-names>WS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>
                  <source>Circulation</source>
                  <year>2018</year>
                  <volume>138</volume>
                  <issue>17</issue>
                  <fpage>e426</fpage>
                  <lpage>e483</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIR.0000000000000597</pub-id>
                  <?supplied-pmid 30354655?>
                  <pub-id pub-id-type="pmid">30354655</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Levin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Stevens</surname>
                      <given-names>PE</given-names>
                    </name>
                  </person-group>
                  <article-title>Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward</article-title>
                  <source>Kidney Int</source>
                  <year>2014</year>
                  <volume>85</volume>
                  <issue>1</issue>
                  <fpage>49</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1038/ki.2013.444</pub-id>
                  <?supplied-pmid 24284513?>
                  <pub-id pub-id-type="pmid">24284513</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brenner</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Cooper</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>de Zeeuw</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy</article-title>
                  <source>N Engl J Med</source>
                  <year>2001</year>
                  <volume>345</volume>
                  <issue>12</issue>
                  <fpage>861</fpage>
                  <lpage>869</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa011161</pub-id>
                  <?supplied-pmid 11565518?>
                  <pub-id pub-id-type="pmid">11565518</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lewis</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Hunsicker</surname>
                      <given-names>LG</given-names>
                    </name>
                    <name>
                      <surname>Clarke</surname>
                      <given-names>WR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes</article-title>
                  <source>N Engl J Med</source>
                  <year>2001</year>
                  <volume>345</volume>
                  <issue>12</issue>
                  <fpage>851</fpage>
                  <lpage>860</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa011303</pub-id>
                  <?supplied-pmid 11565517?>
                  <pub-id pub-id-type="pmid">11565517</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parving</surname>
                      <given-names>HH</given-names>
                    </name>
                    <name>
                      <surname>Lehnert</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Brochner-Mortensen</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes</article-title>
                  <source>N Engl J Med</source>
                  <year>2001</year>
                  <volume>345</volume>
                  <issue>12</issue>
                  <fpage>870</fpage>
                  <lpage>878</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa011489</pub-id>
                  <?supplied-pmid 11565519?>
                  <pub-id pub-id-type="pmid">11565519</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ohkuma</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Jun</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rodgers</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus</article-title>
                  <source>Hypertension</source>
                  <year>2019</year>
                  <volume>73</volume>
                  <issue>1</issue>
                  <fpage>84</fpage>
                  <lpage>91</lpage>
                  <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.12060</pub-id>
                  <?supplied-pmid 30571562?>
                  <pub-id pub-id-type="pmid">30571562</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <mixed-citation publication-type="other">Tsai CW, Huang HC, Chiang HY et al (2018) First-year estimated glomerular filtration rate variability after pre-end-stage renal disease program enrollment and adverse outcomes of chronic kidney disease. Nephrol Dial Transplant. 10.1093/ndt/gfy200</mixed-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Perkovic</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>de Zeeuw</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Mahaffey</surname>
                      <given-names>KW</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials</article-title>
                  <source>Lancet Diabetes Endocrinol</source>
                  <year>2018</year>
                  <volume>6</volume>
                  <issue>9</issue>
                  <fpage>691</fpage>
                  <lpage>704</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2213-8587(18)30141-4</pub-id>
                  <?supplied-pmid 29937267?>
                  <pub-id pub-id-type="pmid">29937267</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wanner</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Heerspink</surname>
                      <given-names>HJL</given-names>
                    </name>
                    <name>
                      <surname>Zinman</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2018</year>
                  <volume>29</volume>
                  <fpage>2755</fpage>
                  <lpage>2769</lpage>
                  <?supplied-pmid 30314978?>
                  <pub-id pub-id-type="pmid">30314978</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leffondre</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Boucquemont</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tripepi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Stel</surname>
                      <given-names>VS</given-names>
                    </name>
                    <name>
                      <surname>Heinze</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Dunkler</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches</article-title>
                  <source>Nephrol Dial Transplant</source>
                  <year>2015</year>
                  <volume>30</volume>
                  <issue>8</issue>
                  <fpage>1237</fpage>
                  <lpage>1243</lpage>
                  <pub-id pub-id-type="doi">10.1093/ndt/gfu320</pub-id>
                  <?supplied-pmid 25326471?>
                  <pub-id pub-id-type="pmid">25326471</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <mixed-citation publication-type="other">van Rijn MHC, Metzger M, Flamant M et al (2018) Performance of creatinine-based equations for estimating glomerular filtration rate changes over time. Nephrol Dial Transplant. 10.1093/ndt/gfy278</mixed-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gaspari</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Ruggenenti</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Porrini</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The GFR and GFR decline cannot be accurately estimated in type 2 diabetics</article-title>
                  <source>Kidney Int</source>
                  <year>2013</year>
                  <volume>84</volume>
                  <issue>1</issue>
                  <fpage>164</fpage>
                  <lpage>173</lpage>
                  <pub-id pub-id-type="doi">10.1038/ki.2013.47</pub-id>
                  <?supplied-pmid 23447062?>
                  <pub-id pub-id-type="pmid">23447062</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Skupien</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Warram</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Smiles</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease</article-title>
                  <source>Kidney Int</source>
                  <year>2012</year>
                  <volume>82</volume>
                  <issue>5</issue>
                  <fpage>589</fpage>
                  <lpage>597</lpage>
                  <pub-id pub-id-type="doi">10.1038/ki.2012.189</pub-id>
                  <?supplied-pmid 22622493?>
                  <pub-id pub-id-type="pmid">22622493</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>MacMahon</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Peto</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Cutler</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias</article-title>
                  <source>Lancet</source>
                  <year>1990</year>
                  <volume>335</volume>
                  <issue>8692</issue>
                  <fpage>765</fpage>
                  <lpage>774</lpage>
                  <pub-id pub-id-type="doi">10.1016/0140-6736(90)90878-9</pub-id>
                  <?supplied-pmid 1969518?>
                  <pub-id pub-id-type="pmid">1969518</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
